{"prompt": "['Study Number: GSP 101-305', 'Version 3.0', 'Date 18-Jul-2018', \"SPONSOR'S SIGNATURE\", \"This protocol reflects the Sponsor's current knowledge of FDC of olopatadine hydrochloride and\", 'mometasone furoate nasal spray (GSP 301 NS) as applicable to this study. It has been designed', 'to achieve the stated objectives while minimizing exposure to, and risk from, both the products', 'being used and the assessments. The assessments are all considered to be appropriate, capable of', 'validating the stated objectives of the study, and of providing the necessary information to ensure', 'subject safety. The protocol has been designed according to the principles of the ICH guidelines', 'for GCP, and the Declaration of Helsinki. lt has undergone both medical and scientific review', 'by the Sponsor. The Sponsor is responsible to regulatory authorities for taking all reasonable', 'steps to ensure the proper conduct of the study as regards ethics, protocol compliance, integrity', 'and validity of the data recorded on the case report forms (CRFs).', 'We hereby agree to conduct the study in accordance with this protocol and the above-', 'mentioned guidance/ /regulation.', 'We agree to comply with all relevant standard operating procedures required for the', 'conduct of this study.', 'We further agree to ensure that all associates assisting in the conduct of study are', 'informed regarding their obligations.', 'Signed on behalf of the Sponsor Glenmark Specialty SA, Switzerland:', '18-Suly-2018', 'Date:', 'Vice President, Clinical Development', 'Glenmark Pharmaceuticals', '461 From Road, Paramus, NJ 07652, USA', 'E-mail:', 'Reviewed and Approved by:', '24- - July 2018', 'Date:', 'President and CMJ', 'Glenmark Pharmaceuticals', '461 From Road, Paramus, NJ 07652, USA', 'E-mail:', 'Glenmark', 'CONFIDENTIAL', 'Page 3 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '1.', 'SYNOPSIS', 'Name of Sponsor/Company: Glenmark Specialty SA', 'Name of Study Drug: GSP 301 NS - Fixed dose combination of olopatadine hydrochloride and mometasone', 'furoate', 'Title of Study: A Double-Blind, Randomized, Parallel-Group Study to Evaluate the Efficacy, Safety and', 'Tolerability of Fixed Dose Combination GSP 301 Nasal Spray Compared With Placebo Nasal Spray in', 'Pediatric Subjects (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)', 'IND no: 123164', 'EudraCT no: Not applicable', 'Phase of development: Phase 3', 'Indication: Seasonal allergic rhinitis (SAR)', 'Objectives:', 'Primary:', 'To compare the efficacy of GSP 301 nasal spray (NS) (administered a:', 'with placebo NS over 14 days of study drug in pediatric subjects (aged >6 to <12 years)', 'with SAR.', 'Secondary:', 'To assess the safety and tolerability over 14 days of study drug in pediatric subjects (aged >6 to', '<12 years) with SAR.', 'Study population: Male and non-pregnant female subjects aged >6 to <12 years with documented clinical', 'history of SAR (for at least 2 years preceding the Screening Visit) with exacerbations (clinical evidence of', 'active symptoms) during the spring or fall allergy seasons for the relevant seasonal allergen (eg, tree/grass', 'pollen or ragweed pollen).', 'Study design: This is a phase 3, double-blind, randomized, parallel-group, placebo-controlled, multicenter', 'study to compare the efficacy and safety of GSP 301 NS with placebo NS in pediatric subjects (aged >6 to', '<12 years) with SAR. A total of approximately 450 subjects (225 subjects randomized to each treatment group)', 'are planned to be randomized in the study. The subject participation may be 22 days up to 27 days with 7 to', '10 days of a placebo run-in period and 14 days of treatment period, with allowable window periods for the', 'study visits.', 'Study endpoints:', 'Primary Endpoint(s):', 'Change from baseline in average morning (AM) and evening (PM) subject-reported 12-hour', 'reflective total nasal symptom score (rTNSS) over the 14-day treatment period.', 'Secondary Endpoint(s):', 'Change from baseline in average AM and PM subject-reported 12-hour instantaneous Total Nasal', 'Symptom Score (iTNSS) over the 14-day treatment period.', 'Change from baseline in the overall Pediatric Rhinoconjunctivitis Quality of Life Questionnaire', '(PRQLQ) score on Day 15 (Visit 4) between treatment groups.', 'Change from baseline in average AM and PM subject-reported 12-hour reflective Total Ocular', 'Symptom Score (rTOSS) over the 14-day treatment period.', 'Other Endpoint(s):', 'Nasal symptoms:', 'Change from baseline in AM subject-reported rTNSS over the 14-day treatment period.', 'Glenmark', 'CONFIDENTIAL', 'Page 4 of 90']\n\n###\n\n", "completion": "END"}